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Abstract To determine the apoptotic signaling pathway which
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/
Apo2L) induced, we investigated the contribution of reactive
oxygen species (ROS), p38 mitogen-activated protein (MAP)
kinase and caspases in human adenocarcinoma HeLa cells.
Here we show that upon TRAIL/Apo2L exposure there was
pronounced ROS accumulation and activation of p38 MAP
kinase, and that activation of caspases and apoptosis followed.
Pretreatment with antioxidants such as glutathione or estrogen
attenuated TRAIL/Apo2L-induced apoptosis through a reduc-
tion of ROS generation and diminished p38 MAP kinase and
caspase activation. The p38 MAP kinase inhibitor SB203580
prevented apoptosis through a blockage of caspase activation,
although ROS generation was not attenuated. Furthermore, the
pan-caspase inhibitor Z-Val-Ala-DL-Asp-fluoromethyl ketone
fully prevented apoptosis, while neither ROS accumulation nor
p38 MAP kinase activation were affected. Therefore, our
results suggest that TRAIL/Apo2L-induced apoptosis is
mediated by ROS-activated p38 MAP kinase followed by
caspase activation in HeLa cells. ß 2002 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing li-
gand (TRAIL/Apo2L) is a member of the TNF family, which
includes TNF, FasL, CD27L, OX40, CD30L, and CD40L
[1,2]. The TNF family is involved in a variety of cellular pro-
cesses, including cell proliferation, di¡erentiation and apopto-
sis [3,4]. TRAIL/Apo2L induces apoptosis by binding to the
death receptor (DR)4 (TRAIL-R1) and DR5 (TRAIL-R2) [5^
7]. Both DR4 and DR5 contain a conserved cytoplasmic re-
gion called ‘death domain’ that is required for DR4- and
DR5-induced apoptosis [6^8]. Binding of TRAIL/Apo2L to
DR4 and DR5 results in activation of the caspase cascade,
presumably through recruiting FADD or related adaptor mol-
ecules [9,10]. However, the intracellular mechanism of
TRAIL/Apo2L-induced apoptosis is not fully understood.
Oxidative stress constitutes a major threat to organisms
living in an aerobic environment, and for humans it might
have a causative role in many disease processes. All aerobic
cells generate reactive oxygen species (ROS) including super-
oxide radical (cO32 ), hydrogen peroxide (H2O2) and hydroxyl
radical (cOH). ROS have been shown to induce various bio-
logical processes, including apoptosis or programmed cell
death [11,12]. For example, ROS have been implicated in
various cytotoxic events including transforming growth factor
L-, ultraviolet radiation (UV)- and 3-hydroxykynurenine-in-
duced cell death [13^15]. In addition, intracellular ROS has
been reported to be involved in TNF induced apoptosis [16].
Mitogen activated protein (MAP) kinase signal transduc-
tion pathways in mammalian cells include the extracellular
signal related kinase (ERK), c-Jun N-terminal kinase (JNK/
SAPK) and p38 MAP kinase. ERK is generally associated
with proliferation and growth factors. In contrast, JNK and
p38 MAP kinase are induced by stress responses and cyto-
kines, and can mediate di¡erentiation and cell death [17^19].
p38 MAP kinase has been distinctively implicated in the reg-
ulation of various cellular processes. The activation of p38
MAP kinase has been observed in a number of physiological
responses such as apoptosis of myocardial cells [20] and adi-
pogenesis in 3T3-L1 cells [21]. A speci¢c inhibitor of p38
MAP kinase blocks apoptosis induced by ceramide [22] and
UV [23]. Moreover, early membrane blebbing during oxida-
tive stress-induced apoptosis is tightly regulated by p38 MAP
kinase-mediated actin organization [24]. Although p38 MAP
kinase has been reported to be involved in various physiolog-
ical events, the mechanism of activation of p38 MAP kinase
by various stimuli as well as its biological roles remain to be
elucidated.
Caspases, a family of aspartate-speci¢c cysteine proteases,
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are the key e¡ectors responsible for many of the morpholog-
ical and biochemical changes of apoptosis [25] and as such are
important in the implementation of apoptosis. The involve-
ment of the caspases in apoptosis has been demonstrated in
an increasing number of biological systems [26]. Furthermore,
evidence for caspase activation was observed in HL-60 cells
following ROS-induced p38 MAP kinase activation [27].
In the present study to explore the intracellular molecular
mechanism of TRAIL/Apo2L, we investigated the possibility
that ROS, p38 MAP kinase and caspases are implicated in
TRAIL/Apo2L-induced apoptosis in HeLa cells. Thereby, we
tried to further elucidate the relationship between these fac-
tors in TRAIL/Apo2L-induced apoptosis. Our results suggest
that TRAIL/Apo2L-induced apoptosis is mediated by ROS-
activated p38 MAP kinase followed by caspase activation in
HeLa cells.
2. Materials and methods
2.1. Cell culture
Human adenocarcinoma HeLa cells were cultured at 37‡C in Dul-
becco’s modi¢ed Eagle’s medium (DMEM) (Life Technologies, Bur-
linton, ON, USA) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS) (Life Technologies) in a humidi¢ed 95% air, 5%
CO2 incubator. The cells were transferred to low serum media (1%
FBS) 2 h before the treatment with recombinant human TRAIL/
Apo2L (Biomol, Plymouth, PA, USA).
2.2. Cell viability assay
Cells were plated on 96-well plates (Corning, NY, USA) at a den-
sity of 5U104 cells/well, in 100 Wl of 10% FBS/DMEM without phenol
red and incubated for 24 h. 2 h before cell stimulation, cell media was
replaced with 90 Wl of 1% FBS/DMEM without phenol red. Plates
were pretreated 2 h with either vehicle, glutathione (GSH; Sigma, St.
Louis, MO, USA), estrogen (17K-estradiol) (Sigma), SB203580 (Cal-
biochem, San Diego, CA, USA) or Z-Val-Ala-DL-Asp-£uoromethyl
ketone (zVAD-fmk; Enzyme System Products, Livermore, CA,
USA) prior to 4 ng/ml TRAIL/Apo2L treatment. 2 h before the
end of the treatment with TRAIL/Apo2L, 10 Wl 10% Triton X-100
and then 11 Wl of 3-(4,5-dimethyl-thiozol-2-yl)-2,5-diphenyl-tetrazo-
lium bromide (MTT; Sigma) 10U solution (10 mg/ml) were added.
At termination all media and MTT solutions were suctioned o¡, cells
and crystallized dyes were dissolved by adding 100 Wl of 100% dime-
thylsulfoxide and shaking for 20 min. Absorbance at 570 nm was
measured with an enzyme-linked immunosorbent assay (ELISA)
Reader (Molecular Devices, Sunnyvale, CA, USA). Following the
addition of 10% Triton X-100, assay values were obtained with vehicle
treatment taken as 100% and MTT reduction de¢ning complete inhi-
bition (0%).
2.3. Determination of ROS generation
Hydrogen peroxide generation induced by TRAIL/Apo2L was mea-
sured by incubation with £uorescent probe 2P,7P-dichloro£uorescein
diacetate (DCF-DA; Sigma). HeLa cells were stained with 10 WM of
DCF-DA for 30 min. Cells were collected and washed twice with
phosphate-bu¡ered saline (PBS). Cells were put on slide-glasses and
were analyzed on a £uorescent microscope (Olympus IX 70, Tokyo,
Japan).
2.4. Western blotting
For Western blot analysis, HeLa cells were washed with PBS, the
cells pelleted and then lysed by the addition of cold RIPA bu¡er (1%
Triton X-100, 20 mM Tris^HCl, pH 7.5, 100 mM NaCl, 1 mM
Na3VO4, 40 mM NaF, 5 mM EGTA, 0.2% sodium dodecyl sulfate
(SDS), 0.2 mM phenylmethylsulfonyl £uoride, 100 WM leupepsin).
The cell lysate was centrifuged at 15 800Ug at 4‡C for 10 min. The
supernatant was harvested and analyzed for protein content using a
protein assay kit (Bio-Rad, Hercules, CA, USA). For electrophoresis,
proteins (80 Wg) were dissolved in sample bu¡er (5% L-mercaptoeth-
anol, 15% glycerol, 3% SDS, 0.1 M Tris, pH 6.8), boiled for 3 min,
and then separated on a 10% SDS gel under reducing conditions. The
separated proteins were transferred onto polyvinylidene di£uoride
membranes using a semidry trans-blot system (Schleicher and Schuell,
Germany). The blots were blocked for 2 h at room temperature with
Tris-bu¡ered saline (TBS) (10 mM Tris, pH 7.5, 100 mM NaCl) con-
taining 5% non-fat dry milk. The blots were washed three times with
TBS, and then incubated at room temperature overnight with anti-p38
MAP kinase antibodies (1:1000 dilution) (Santa Cruz Biotech, Santa
Cruz, CA, USA) or anti-phospho-p38 MAP kinase antibodies (1:1000
dilution) (Santa Cruz Biotech) in TBST (10 mM Tris, pH 7.5, 100
mM NaCl, 0.05% Tween 20) containing 3% non-fat dry milk. The
next day the blots were washed three times with TBST, and then
incubated for 2 h at room temperature with horseradish peroxidase-
conjugated secondary antibodies (1:2000 dilution) (Santa Cruz Bio-
Fig. 1. E¡ect of GSH, SB203580, or zVAD-fmk on TRAIL/Apo2L-induced cell death. A: HeLa cells were pretreated with 10 WM of GSH,
10 WM of SB203580, or 10 WM of zVAD-fmk for 2 h and then treated with 4 ng/ml of TRAIL/Apo2L. Cell viability was determined at indi-
cated time points. B: A bar graph of cell viability as by the MTT assay at 36 h after 4 ng/ml TRAIL/Apo2L treatment. Values, presented as
percentage of control cells incubated with vehicle, are mean þ S.E.M. of four separate experiments. *The di¡erence from the cells treated with
TRAIL/Apo2L alone was statistically signi¢cant (P6 0.05).
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tech) in TBST containing 3% non-fat dry milk. After washing three
times with TBST, the protein was visualized using the enhanced chem-
iluminescence detection system (Amersham Pharmacia Biotech, UK).
The relative protein levels were determined using densitometry (Vilber
Lourmat, France) normalizing to the p38 MAP kinase band on a
duplicate blot.
2.5. Caspase substrate cleavage assay
HeLa cells were collected by centrifugation at 150Ug for 10 min,
and the washed cell pellet was resuspended in 100 Wl of lysis bu¡er
containing 50 mM Tris, pH 7.5, 0.03% NP-40, and 1 mM dithiothrei-
tol. The lysates were incubated on ice for 20 min with intermittent
vortex and then centrifuged at 15 800Ug for 5 min. The supernatant
was harvested and analyzed for its protein content using a protein
assay kit (Bio-Rad). To assess caspase cleavage, 20 Wg of cellular
extracts were incubated with 0.25 mM zVAD-PNA (Enzyme System
Products), a substrate of pan-caspase, in 100 Wl of total volume at
37‡C for 1 h. Absorbance at 405 nm was measured with an ELISA
Reader (Molecular Devices). Enzymatic activity is expressed as arbi-
trary units of relative value.
2.6. Statistical analysis
Data are expressed as mean þ S.E.M. values. Student t-test was
applied to study the relationship between the di¡erent variables. A
P6 0.05 was considered to be signi¢cant.
3. Results
3.1. Involvement of ROS and p38 MAP kinase in
TRAIL/Apo2L-induced apoptosis
To investigate the involvement of ROS in TRAIL/Apo2L-
induced apoptosis, a £uorescent analysis with DCF-DA was
performed to quantify intracellular levels of ROS. As shown
in Fig. 2A,B,G, when cells were treated with 4 ng/ml of
TRAIL/Apo2L for 1 h, the intensities of DCF £uorescence
showed signi¢cant, above ¢ve-fold increases, than those in
untreated cells. The increase in DCF £uorescence was largely
attenuated by pre-incubation of antioxidant such as GSH or
estrogen (Fig. 2C,D), indicating that the increased £uores-
cence re£ects increased levels of intracellular ROS. Pre-incu-
bation of the HeLa cells with antioxidants e¡ectively pre-
vented TRAIL/Apo2L-induced apoptosis corroborates (Fig.
1A,B). These results implicate ROS in TRAIL/Apo2L-in-
duced apoptosis in HeLa cells.
To identify the activation of p38 MAP kinase in TRAIL/
Apo2L-treated HeLa cells, we used polyclonal antibody that
recognizes only the activated, phosphorylated form of p38
MAP kinase. As shown in Fig. 3, TRAIL/Apo2L strongly
stimulated p38 MAP kinase activation. In HeLa cells exposed
to TRAIL/Apo2L, the p38 MAP kinase activity was increased
within 0.5 h, reached the maximum at 2 h, and returned to
basal levels at 12 h. Total levels of p38 MAP kinase were not
a¡ected by treatment of TRAIL/Apo2L and were therefore
used as an internal standard in quanti¢cation of p38 MAP
kinase activation. To address the contribution of p38 MAP
kinase to induce cell death in HeLa cells, we examined the
e¡ect of p38 MAP kinase inhibition on TRAIL/Apo2L-in-
duced apoptosis. Concurrent addition of 10 WM of
SB203580, a speci¢c inhibitor of p38 MAP kinase, e¡ectively
prevented TRAIL/Apo2L-induced apoptosis (Fig. 1A,B) and
attenuated p38 MAP kinase activation induced by TRAIL/
Apo2L (Fig. 4A,B). These results indicate that TRAIL/
Apo2L strongly activates p38 MAP kinase in TRAIL/
Apo2L-induced apoptosis, contributing to the potential induc-
tion of the apoptotic cascade.
3.2. Activation of p38 MAP kinase by TRAIL/Apo2L-induced
ROS
To assess whether p38 MAP kinase activation is induced by
ROS, we studied the e¡ect of pretreatment with antioxidants
on TRAIL/Apo2L-induced p38 MAP kinase activation. As
shown in Fig. 4, the p38 MAP kinase activation induced by
TRAIL/Apo2L was e¡ectively inhibited by pretreatment with
10 WM of GSH or 100^500 nM of estrogen. Although, the
pretreatment with 10 WM of SB203580 did not attenuate
TRAIL/Apo2L-induced ROS generation (Fig. 2F,G). As ob-
served in untreated cells, treatment with SB203580 alone did
not a¡ect the ROS generation (Fig. 2E,G). Therefore, these
Fig. 2. Determination of ROS generation levels by TRAIL/Apo2L
after pretreatment with GSH, estrogen, or SB203580. HeLa cells
were untreated (A) or treated (B) with 4 ng/ml of TRAIL/Apo2L
for 1 h. Pretreatment of HeLa cells with 10 WM of GSH (C) or
100 nM of estrogen (D) were treated with 4 ng/ml of TRAIL/
Apo2L for 1 h. Pretreatment of HeLa cells with 10 WM of
SB203580 were either not treated (E) or treated (F) with 4 ng/ml of
TRAIL/Apo2L for 1 h. Hydrogen peroxide generation induced by
TRAIL/Apo2L was measured by incubation with £uorescent probe
2, DCF-DA. The ¢gures are representative for four di¡erent experi-
ments. G: Quanti¢cation of £uorescent levels (results of A^F).
Fluorescent levels are expressed as arbitrary units of relative value.
*The di¡erence from the cells treated with TRAIL/Apo2L alone
was statistically signi¢cant (P6 0.05).
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results suggest that ROS activates p38 MAP kinase in
TRAIL/Apo2L-induced apoptosis.
3.3. Caspase activation by ROS-activated p38 MAP kinase in
TRAIL/Apo2L-induced apoptosis
To determine whether caspase activation is functionally im-
portant for TRAIL/Apo2L-induced apoptosis, cells were pre-
incubated with the pan-caspase inhibitor zVAD-fmk. The pre-
treatment with 10 WM of zVAD-fmk signi¢cantly prevented
cell death following a 36 h exposure to 4 ng/ml of TRAIL/
Apo2L (Fig. 1A,B). Caspase activity was measured by cleav-
age of zVAD-PNA, a substrate of pan-caspase. As shown in
Fig. 5, the caspase activity in TRAIL/Apo2L-treated HeLa
cells increased over 10-fold compared with untreated cells.
In addition, the pretreatment with 10 WM of zVAD-fmk
blocked caspase activation. These results suggest that
TRAIL/Apo2L-induced apoptosis occurs through the activa-
tion of common executors of apoptosis such as caspase-3.
To investigate the intracellular mechanism of caspase acti-
vation in TRAIL/Apo2L-induced cytotoxicity, we examined
the e¡ect of pretreatment with GSH or SB203580 on
Fig. 3. Western blot analysis of p38 MAP kinase in TRAIL/Apo2L
treated HeLa cells. A: HeLa cells were untreated (control; lane 1)
or treated with 4 ng/ml of TRAIL/Apo2L for 0.5 (lane 2), 1 (lane
3), 2 (lane 4), 4 (lane 5), 6 (lane 6), 12 (lane 7), 24 (lane 8) and 36
h (lane 9). The phosphorylation state of p38 MAP kinase was de-
tected by Western blotting with a phosphospeci¢c p38 MAP kinase
antibody at indicated time points (p-p38). The same samples were
probed with p38 MAP kinase antibody as a loading control (p38).
B: Quanti¢cation of A results. Total levels of p38 MAP kinase
were used as an internal standard in quanti¢cation of phosphorylat-
ed p38 MAP kinase. The levels of p38 MAP kinase are expressed as
arbitrary units of relative value. *The di¡erence from the cells incu-
bated with vehicle alone was statistically signi¢cant (P6 0.05).
6
Fig. 4. E¡ect of SB203580, GSH or estrogen on TRAIL/Apo2L-activated p38 MAP kinase. A: HeLa cells were untreated (control; lane 1).
Cells were left untreated (lane 2) or incubated with either 5 WM of SB203580 (lane 3), 10 WM of SB203580 (lane 4), 5 WM of GSH (lane 5),
10 WM of GSH (lane 6), 100 nM of estrogen (lane 7) or 500 nM of estrogen (lane 8) for 2 h, followed by treatment with 4 ng/ml of TRAIL/
Apo2L for 2 h. The phosphorylation state of p38 MAP kinase was detected by Western blotting with a phosphospeci¢c p38 MAP kinase anti-
body (p-p38). The same samples were probed with p38 MAP kinase antibody as a loading control (p38). B: Quanti¢cation of A results. Total
levels of p38 MAP kinase were used as an internal standard in quanti¢cation of phosphorylated p38 MAP kinase. The levels of p38 MAP ki-
nase are expressed as arbitrary units of relative value. *The di¡erence from the cells incubated with vehicle alone was statistically signi¢cant
(P6 0.05).
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TRAIL/Apo2L-induced caspase activation. As shown in Fig.
5, the caspase activity was e¡ectively reduced by pretreatment
with 10 WM of GSH or SB203580. In contrast, the pretreat-
ment with 10 WM of zVAD-fmk did not signi¢cantly reduce
the accumulation of ROS and the activation of p38 MAP
kinase induced by TRAIL/Apo2L (data not shown). These
results indicate that ROS-activated p38 MAP kinase plays a
role as an upstream regulator of caspase activation in TRAIL/
Apo2L-induced apoptosis.
4. Discussion
Because TRAIL/Apo2L selectively induces apoptosis in tu-
mor but not in normal cells, it has shown great potential to be
a valuable tumor therapeutic agent [28]. However, the intra-
cellular mechanisms of TRAIL/Apo2L-induced apoptosis are
not fully understood. Thus, we tried to investigate the intra-
cellular signaling of TRAIL/Apo2L. Our results show that
ROS is involved in TRAIL/Apo2L-induced apoptosis in
HeLa cells. TRAIL/Apo2L-induced apoptosis is inhibited by
antioxidants such as GSH or estrogen, and this inhibition is
correlated with a decrease in TRAIL/Apo2L-induced ROS
formation. TRAIL/Apo2L-induced ROS generation and/or
electrostatic incongruities may obstruct mitochondrial metab-
olism, altering the balance of biochemical chains of events,
leading to a further increase in ROS generation, consequently
entering into an intractable cycle of toxic events, eventually
leading to cellular apoptosis.
In this study, we demonstrate that treatment of HeLa cells
with TRAIL/Apo2L results in a rapid phosphorylation of p38
MAP kinase. Activation of p38 MAP kinase occurs within 0.5
h after exposure to TRAIL/Apo2L, which is prior to the onset
of apoptosis. Also, p38 MAP kinase activity was functionally
inhibited by SB203580. This inhibitor was reported to be
highly speci¢c for p38 MAP kinase both in vitro and in
vivo [29]. A number of studies indicate that activation of
p38 MAP kinase plays a crucial role in apoptosis induced
by various stimuli. For example, activation of p38 MAP ki-
nase is required for apoptosis induced by nerve growth factor
depletion in PC12 neuronal cells [30]. In U937 and Jurkat
cells, interfering with p38 MAP kinase has been shown to
block apoptosis induced by ceramide and UV radiation
[22,23]. Activation of p38 MAP kinase has also been impli-
cated in anticancer drug-induced apoptosis [31]. Thus, the
pretreatment of SB203580 was e¡ective in preventing
TRAIL/Apo2L-induced apoptosis, suggesting that p38 MAP
kinase is required for the apoptosis induced by TRAIL/
Apo2L.
Our results also show that the activation of p38 MAP ki-
nase induced by TRAIL/Apo2L is e¡ectively inhibited by pre-
treatment of GSH and estrogen, implicating that TRAIL/
Apo2L-induced ROS acts upstream of p38 MAP kinase and
participate in activation of p38 MAP kinase. Previous studies
have shown that p38 MAP kinase is responsive to ROS and
involved in apoptosis [14]. For example, nitric oxide induces
the activation of p38 MAP kinase in HL-60 cells [32] and
H2O2 preferentially stimulates the phosphorylation of p38
MAP kinase in vascular cells [33]. Recently, another study
has reported that p38 MAP kinase is activated by ROS-acti-
vated STE20-related protein kinases [34].
Previous studies have shown that the caspase inhibitor ef-
fectively prevents TRAIL/Apo2L receptor- [35] and Fas-medi-
ated apoptosis [36], suggesting that caspase plays an essential
role in TRAIL/Apo2L receptor- and Fas-mediated signaling.
In this study, we show that the pretreatment with zVAD-fmk
could completely inhibit TRAIL/Apo2L-induced apoptosis in
HeLa cells. However, this inhibition of caspase activities did
not attenuate ROS generation and p38 MAP kinase activation
by TRAIL/Apo2L, suggesting that caspases act downstream
of ROS and p38 MAP kinase. Also, the treatment of HeLa
cells with antioxidants or SB203580 attenuates the activation
of caspases induced by TRAIL/Apo2L. Therefore, our results
indicate that caspases which are activated by phosphorylated
p38 MAP kinase may play an essential role in TRAIL/
Apo2L-induced apoptosis.
In summary, this report is the ¢rst to show that TRAIL/
Apo2L-induced apoptosis is mediated by ROS-activated p38
MAP kinase followed by caspase activation in HeLa cells.
Understanding this intracellular mechanism of TRAIL/
Apo2L-induced apoptosis may help to optimize TRAIL/
Apo2L as a therapeutic agent in cancer.
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